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Abstract
Myelin and axon losses are associated with cognitive decline in healthy ageing but 
are worse in people diagnosed with tauopathy. To determine whether tauopathy is 
also associated with enhanced myelin plasticity, we evaluated the behaviour of OPCs 
in mice that expressed a human pathological variant of microtubule-associated pro-
tein tau (MAPTP301S). By 6 months of age (P180), MAPTP301S mice overexpressed 
hyperphosphorylated tau and had developed reactive gliosis in the hippocampus but 
had not developed overt locomotor or memory impairment. By performing cre-lox 
lineage tracing of adult OPCs, we determined that the number of newborn oligoden-
drocytes added to the hippocampus, entorhinal cortex and fimbria was equivalent in 
control and MAPTP301S mice prior to P150. However, between P150 and P180, sig-
nificantly more new oligodendrocytes were added to these regions in the MAPTP301S 
mouse brain. This large increase in new oligodendrocyte number was not the result 
of increased OPC proliferation, nor did it alter oligodendrocyte density in the hip-
pocampus, entorhinal cortex or fimbria, which was equivalent in P180 wild-type and 
MAPTP301S mice. Furthermore, the proportion of hippocampal and fimbria axons with 
myelin was unaffected by tauopathy. However, the proportion of myelinated axons 
that were ensheathed by immature myelin internodes was significantly increased in 
the hippocampus and fimbria of P180 MAPTP301S mice, when compared with their 
wild-type littermates. These data suggest that MAPTP301S transgenic mice experience 
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1 |  INTRODUCTION
In healthy ageing, white matter damage can be detected in 
brain regions that are critical for cognitive and emotional 
processing, including the hippocampus, neocortex and fron-
tal white matter tracts, and the extent of white matter dam-
age closely correlates with cognitive decline (Charlton et al., 
2006; Fan et al., 2019; Hirsiger et al., 2017). However, white 
matter degeneration is exacerbated in people diagnosed with a 
tauopathy. In people with frontotemporal dementia, fractional 
anisotropy, as measured by diffusion tensor imaging, is re-
duced in frontal and temporal white matter regions, including 
the anterior corpus callosum, anterior cingulum tracts and un-
cinate tracts, when compared with healthy controls (Kassubek 
et al., 2018; Lu et al., 2014; Zhang et al., 2009). Similar stud-
ies show that people with Alzheimer's disease have reduced 
fractional anisotropy in parietal, temporal and frontal regions 
including the corpus callosum, cingulum and uncinate tracts, 
compared with controls (Benitez et al., 2014; Brueggen et al., 
2019; Choi, Lim, Monteiro, & Reisberg, 2005; O’Dwyer et al., 
2011; Stricker et al., 2009; Zhang et al., 2009). In these tauop-
athies, the observed white matter degeneration likely reflects 
a combination of myelin breakdown and axon degeneration.
Tauopathies are a group of diseases characterised by the 
aggregation of hyperphosphorylated tau in neurons and glial 
cells, including myelinating oligodendrocytes (reviewed by 
Ferrer, 2018). Tau aggregates in cells of the oligodendrocyte 
lineage are referred to as coiled bodies and threads and have 
been identified in post-mortem tissue from people diagnosed 
with Pick's disease (Arai et al., 2001; Komori, 1999; Mimuro 
et al., 2010), progressive supranuclear palsy (Arai et al., 
2001; Arima et al., 1997; Jin et al., 2006; Komori, 1999; 
Nishimura, Ikeda, et al., 1995), corticobasal degeneration 
(Arai et al., 2001; Feany & Dickson, 1995; Komori, 1999; 
Wakabayashi et al., 1994), frontotemporal lobar degeneration 
associated with variants in microtubule-associated protein 
tau (MAPT) (Higuchi et al., 2005) and Alzheimer's disease 
(Nishimura, Tomimoto, et al., 1995). Frontotemporal demen-
tia is also associated with myelin degeneration in the frontal 
white matter, and Alzheimer's disease results in an early and 
progressive reduction in white matter cholesterol and myelin 
proteins, such as myelin basic protein, proteolipid protein and 
2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) (Roher 
et al., 2002), and a reduction in CNP expression (Vlkolinský 
et al., 2001) and impaired myelin lipid synthesis (Couttas 
et al., 2016) in the frontal grey matter. Myelin degeneration 
is also detected post-mortem in the frontal and periventricu-
lar white matter regions of people with Alzheimer's disease 
(Ihara et al., 2010; Zhan et al., 2014), and a recent proteomics 
study revealed that myelin sheath components are signifi-
cantly reduced in the frontal cortex of people with sporadic 
Alzheimer's disease (Zhang et al., 2018).
Tauopathy-like oligodendrocyte pathology can be induced 
in mice by the injection of brain tissue homogenates from peo-
ple who had sporadic Alzheimer's disease, primary age-related 
tauopathy, ageing-related tau astrogliopathy, globular glial 
tauopathy, progressive supranuclear palsy, Pick's disease or 
frontotemporal lobar degeneration (linked to the MAPTP301L 
variant), into the corpus callosum. Phospho-tau deposits devel-
oped inside cells of the oligodendrocyte lineage and myelin dis-
ruption was evident within 6 months of injection (Ferrer et al., 
2019). However, a separate study found that tau-inclusions were 
rarely seen in mice inoculated with Alzheimer's disease homog-
enates but were a common feature following inoculation with 
corticobasal degeneration homogenates (Boluda et al., 2015).
Transgenic mice that express human tauopathy-asso-
ciated variants in MAPT, primarily the MAPTP301L and 
MAPTP301S variants, also recapitulate many of the aspects 
of human tauopathy, including the development of gliosis, 
the formation of neurofibrillary tangles, neuron loss, and 
motor and cognitive impairment (Lewis et al., 2000; Lin, 
Lewis, Yen, Hutton, & Dickson, 2003a, 2003b; Ramsden 
et al., 2005; Ren et al., 2014; Santacruz et al., 2005; Takeuchi 
et al., 2011; Yoshiyama et al., 2007). In the spinal cord of 
the Prnp-MAPTP301L transgenic mice, oligodendrocytes also 
undergo apoptosis (Zehr et al., 2004). Furthermore, when 
three human tauopathy MAPT variants are expressed under 
the control of the mouse α-tubulin promoter, in the absence 
of endogenous Mapt, coiled bodies form inside spinal cord 
oligodendrocytes, and oligodendrocyte number is reduced by 
6 months of age—prior to neuron loss (Higuchi et al., 2002). 
Consistent with these findings, the expression of MAPTP301L 
in CamKIIa+ neurons was associated with thinner myelin en-
sheathing perforant pathway axons that project from the en-
torhinal cortex to the hippocampus (Jackson et al., 2018), and 
when expression of this variant was restricted to oligoden-
drocytes (CNP promoter), myelin degeneration and axon loss 
from the spinal cord were detected prior to the development 
of tau aggregates in oligodendrocytes or oligodendrocyte loss 
(Higuchi et al., 2005).
significant oligodendrocyte turnover, with newborn oligodendrocytes compensating 
for myelin loss early in the development of tauopathy.
K E Y W O R D S
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It is possible that oligodendrogenesis occurs alongside 
oligodendrocyte loss in tauopathy, as oligodendrocyte pro-
genitor cells (OPCs) have the ability to proliferate and dif-
ferentiate to produce new oligodendrocytes in response to 
oligodendrocyte loss and demyelination (Assinck et al., 2017; 
Baxi et al., 2017; Tripathi et al., 2010; Zawadzka et al., 2010). 
This has not been examined in detail in preclinical models 
of tauopathy; however, young adult Thy1.2-MAPTP301S mice 
may remyelinate more effectively than controls. Following 
a focal injection of lysolecithin into the spinal cord ventral 
funiculus, OPC density was maintained, but the density of 
oligodendrocytes and the expression of myelin basic protein 
were elevated at the lesion site of Thy1.2-MAPTP301S mice 
compared with demyelinated wild-type controls (Ossola et al., 
2016). In this study, we demonstrate that the overexpression 
of MAPTP301S, primarily in neurons, results in a large number 
of new oligodendrocytes accumulating in the hippocampus, 
entorhinal cortex and fimbria between 5 and 6 months of age, 
and an increase in the number of axons ensheathed by imma-
ture myelin internodes. As this increase in oligodendrocyte 
addition occurred prior to axon loss or the development of 
overt cognitive deficits and did not increase oligodendrocyte 
density or the proportion of axons that were myelinated in 
these regions, it is likely that new oligodendrocyte addition 
facilitates oligodendrocyte and myelin maintenance as early 
pathology develops in the central nervous system (CNS) of 
MAPTP301S transgenic mice.
2 |  MATERIALS AND METHODS
2.1 | Animals
Rosa26-YFP cre-sensitive reporter mice (Srinivas et al., 2001) 
were purchased from the Jackson Laboratory [B6.129X1-
Gt(ROSA)26Sortm1(EYFP)Cos/J, stock #006148] and 
backcrossed onto a C57BL/6 background in house for >10 
generations. Prnp-MAPTP301S (MAPTP301S) transgenic mice 
(Yoshiyama et al., 2007), that express a human variant of 
MAPT, were purchased from the Jackson Laboratory [B6;C3-
Tg(Prnp-MAPT*P301S)PS19Vle/J, stock #008169] and 
backcrossed onto a C57BL/6 background for >20 genera-
tions. Pdgfrα-CreERT2 transgenic mice (Rivers et al., 2008) 
were a kind gift from Prof. William D Richardson (University 
College London, UK). Mice were maintained on a C57BL/6 
background and bred to generate experimental mice that were 
heterozygous for each transgene. Male and female mice were 
housed in individually ventilated cages (Optimice) on a 12-hr 
light/dark cycle (07:00–19:00), with food and water avail-
able ad libitum. All animal experiments were approved by 
the Animal Ethics Committee of the University of Tasmania 
(13,741 and 16,151) and carried out in accordance with the 
Australian code of practice for the care and use of animals 
in science. Details of animal experiments are reported in ac-
cordance with the ARRIVE guidelines.
2.2 | Genotyping
Genomic DNA extractions and the detection of the Cre re-
combinase and the Rosa26-YFP transgenes by polymer-
ase chain reaction (PCR) were carried out as previously 
described (O’Rourke et al., 2016). Each PCR to detect the 
MAPT transgene was carried out using Taq DNA polymerase 
with standard Magnesium-free Taq buffer (M0329L; New 
England BioLabs) and deoxynucleotide (dNTP) solution mix 
(N0447L; New England BioLabs), with the following prim-
ers: MAPT 5′ GGG GAC ACG TCT CCA CGG CAT CTC 
AGC AAT GTC TCC and MAPT 3′ TCC CCC AGC CTA 
GAC CAC GAG AAT, and was heated to 94°C for 4 min and 
amplified across 35 cycles of 94°C for 30s, 57°C for 45s and 
72°C for 60s, followed by a final 10 min at 72°C, to yield a 
DNA fragment of ~350 bp. DNA products were run on a 2% 
(w/v) agarose gel in TAE containing SYBR safe (Thermo 
Fisher Scientific) and visualised using an Amersham Imager 
600 (Ge Healthcare Life Sciences, UK).
2.3 | Tamoxifen preparation and delivery
Tamoxifen (Sigma; cat # T5648) was dissolved in corn 
oil (40 mg/ml) by sonication (Ultrasonic cleaner FXP 8M, 
Unisonics Australia) at 21°C for 2  hr. For lineage trac-
ing, adult mice (P60) received 300 mg tamoxifen/kg body 
weight daily for four consecutive days by oral gavage as 
previously described (O’Rourke et al., 2016). Mice were 
analysed 7, 90 or 120 days after their first dose of tamoxifen 
and are referred to as P60 + 7, P60 + 90 and P60 + 120, 
respectively.
2.4 | Western blotting
Mice were terminally anaesthetised using sodium pento-
barbital (i.p 100  mg/kg) and transcardially perfused with 
ice-cold 0.01 M phosphate-buffered saline (PBS; n  =  3 
mice per group). On ice, the dorsal region of the hip-
pocampus was collected from 2mm thick coronal slices 
spanning Bregma −1.06 to −2.06 (Franklin & Paxinos, 
2007), and then prepared and analysed by Western blot as 
per Auderset, Cullen, and Young (2016). Briefly, precast 
Bolt™ 4%–12% Bis-Tris Plus Gels (Life Technologies, 
Australia) were run for 1  hr at 21°C and 90v, followed 
by 20 min at 165v. The proteins were transferred onto an 
ethanol-activated PVDF membrane (BioRad) over a 60-
min period at 20v and 4°C. The membrane was blocked 
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for 1 hr at 21°C by immersion in 0.2% (v/v) Tween-20 in 
Tris-buffered saline (TBS-T) containing 5% (w/v) skim 
milk powder, before being transferred to TBS-T contain-
ing 5% (w/v) skim milk powder and either rabbit anti-E178 
(1:1,000, Abcam; detects human and mouse tau) or rabbit 
anti-Thr231 (1:1,000, Abcam; detects human and mouse 
phosphorylated tau) overnight at 4°C. Each membrane was 
washed thrice in TBS-T before being incubated for 1  hr 
at 21°C in TBS-T containing 1% (w/v) skim milk pow-
der and goat anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (1:10,000, Dako). Each 
membrane was washed in TBS-T before being exposed 
to a 1:1 mix of Immobilon Western™ HRP Peroxidase 
Solution (Millipore) and Luminol Reagent (Millipore), to 
visualise the protein bands on an Amersham Imager 600 
(Ge Healthcare Life Sciences, UK). To control for protein 
loading, membranes were washed with PBS, TBS-T and 
blot stripping buffer (ThermoScientific), incubated for 1h 
at 21°C with mouse anti-β-actin (1:1,000, Sigma), washed 
thrice in TBS-T and incubated for 1 hr at 21°C with sec-
ondary goat anti-mouse HRP (1:10,000, Dako). Western 
blot band intensity was calculated by measuring integrated 
density and normalising this signal to β-actin protein ex-
pression levels.
2.5 | Locomotor and cognitive testing
Behavioural testing was carried out for MAPT301S trans-
genic mice, their wild-type (WT) littermates and C57BL/6 
mice in separate cohorts at 60 (n = 23 WT, 9 MAPTP301S), 
90 (n = 24 WT, 12 MAPTP301S) and 180 (n = 24 WT, 13 
MAPTP301S) days of age. All behavioural testing was car-
ried out during the dark phase of the light–dark cycle. 
Mice were moved to the testing room 2  hr prior to the 
light cycle change and habituated to the room for 3 hr. All 
testing was carried out within the same 5-hr window of 
the dark phase. Sodium lights were used in the room, and 
bright lights were used above the maze as needed. All trials 
were video recorded and animal movement tracked using 
automated tracking software (EthoVision XT 11, Noldus, 
Netherlands). Males were tested prior to females, but the 
order of testing was otherwise randomised between ses-
sions. All equipment was cleaned with 70% ethanol be-
tween trials.
T-Maze: The T-maze was performed using a protocol 
adapted from Deacon and Rawlins (2006). A mouse was 
placed in the start arm, and once they chose to explore the left 
or right arm of the maze, retreat from that arm was blocked 
for 1  min. The mouse was then returned to the start arm 
and allowed to make another choice. This was repeated 10 
times. Mice naturally exhibit exploratory behaviour and tend 
to choose the arm not visited in the previous trial; therefore, 
returning to the same arm in successive trials was recorded 
as an error.
Open field and novel object recognition: On day 1, we 
carried out an open field assessment using a protocol adapted 
from Wang et al. (2013), to assess locomotor and anxiety-like 
behaviour. Each mouse was placed in an open square arena 
(30 cm2, with walls of 20 cm in height) lit (200 lux) to create a 
bright centre and dark perimeter, and the speed of movement 
and total distance moved was measured over a 10 min period. 
On day 2, the arena was uniformly illuminated (50 lux) and 
contained two identical objects (multi-coloured green and 
blue Lego towers), equidistant from the box edges (7.5 cm 
away from the box edges). Each mouse was left to explore the 
arena and familiarise themselves with the identical objects 
for 10  min. On day 3, one of the familiarised objects was 
replaced by a novel object (a multi-coloured green and blue 
Lego man) that was of similar size and colour, but a different 
shape and texture. Each mouse was returned to the arena and 
left to explore for 5 min. The time spent exploring each object 
was recorded, and the proportion of time exploring the novel 
object was calculated as an indication of short-term recogni-
tion memory.
Barnes Maze: Mice underwent a shortened version of 
the Barnes maze protocol, adapted from Attar et al. (2013). 
On day 1, mice were placed in the brightly lit centre (120 
lux) of an elevated (30 cm above the ground), circular maze 
(100  cm diameter) that contained 20 holes evenly spaced 
around the circumference. After 1 min, the mice were gen-
tly directed to an escape box located underneath one of the 
holes in the circumference and left to habituate to the box 
for 5 min. On days 2 and 3, the maze was raised to 70 cm, 
and light intensity in the centre of the maze increased to 160 
lux. Distinct patterns were placed on each wall surrounding 
the maze, acting as spatial reference points that remained 
consistent throughout all trials. At the start of each trial, 
each mouse was placed at the centre of the maze under a 
covered start box for 15–30 s before the box was removed, 
and the mouse left to explore until they found the escape 
box or 5 min elapsed. If a mouse did not find the escape box 
prior to the end of trial, it was given direction to the box 
and allowed to enter it. After entering the escape box, each 
mouse was left for 1 min before being returned to the home 
cage to await the next trial. Mice were trained to learn the 
location of the escape box across 3 trials per day with an 
inter-trial interval of 30–45 min. During training, approach-
ing any hole that did not lead to the escape box was consid-
ered a primary error, and the number of primary errors made 
during a trial was measured as an indicator of learning (re-
viewed by Gawel, Gibula, Marszalek-Grabska, Filarowska, 
& Kotlinska, 2019).
Short-term memory and long-term memory were assessed 
1 day and 2 weeks after initial training, respectively. For each 
memory probe trial, mice were returned to the maze, with the 
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escape box now removed, and were left to explore the maze 
for 5 min. The maze was divided into four quadrants within 
the tracking software (EthoVision XT 11) and the quadrant 
containing the hole that previously led to the escape hole 
was designated the target zone. The proportion of time spent 
within the target zone during the probe trial was measured as 
an indicator of intact memory for the location of the escape 
box.
2.6 | Immunohistochemistry
Tissue fixation and cryoprotection were performed as pre-
viously described (O’Rourke et al., 2016). About 30  µm 
coronal brain cryosections containing the hippocampus, en-
torhinal cortex and fimbria (Bregma −1.34 to −2.7; Franklin 
& Paxinos, 2007) were collected and processed as floating 
sections. Cryosections were incubated for 1 hr at 21°C in 
blocking solution [10% foetal calf serum (FCS)/ 0.1% tri-
ton x-100 in PBS] before being placed on an orbital shaker 
overnight at 4°C in blocking solution containing primary 
antibodies [goat anti-PDGFRα (1:100, R&D Systems); 
rat anti-GFP (1:2000, Nacalai Tesque); rabbit anti-OLIG2 
(1:400, Merck Millipore); rabbit anti-ASPA (1:200, Merck 
Millipore); rabbit anti-Ki67 (1:200, Abcam); mouse anti-
NaBC1 (BCAS1; 1:200, Santa Cruz) or guinea pig anti-
Iba1 (1:250, Synaptic Systems)]. Sections were washed 
thrice in PBS before being placed on an orbital shaker at 
4°C overnight, in blocking solution containing secondary 
antibodies, conjugated to Alexa Fluors [Life Technologies 
Corporation: donkey anti-rat 488 (1:500); donkey anti-
goat 568 (1:1,000); donkey anti-rabbit 647 (1:1,000), don-
key anti-goat 647 (1:1,000) or goat anti-guinea pig 488 
(1:1,000)]. Cell nuclei were visualised by the inclusion of 
Hoechst 33342 (1:10,000, Invitrogen). Floating sections 
were mounted onto glass slides and the fluorescence pre-
served by the application of fluorescent mounting medium 
(Dako Australia Pty. Ltd., Campbellfield, Australia).
2.7 | EdU administration and detection
5-Ethynyl-2′-deoxyuridine (EdU; Invitrogen) was adminis-
tered to P175 mice (n = 6 WT, n = 3 MAPTP301S) via their 
drinking water (0.2 mg/ml, as per Young et al., 2013) for five 
consecutive days. EdU-labelled cells were visualised using 
the AlexaFluor-647 Click-iT EdU kit (Invitrogen). Briefly, 
30  µm floating cryosections were incubated for 15  min in 
0.5% Triton X-100 (v/v) in PBS at room temperature before 
being transferred into the EdU developing cocktail and in-
cubated for 45 min in the dark. Cryosections were washed 
twice in PBS before carrying out immunohistochemistry as 
described above.
2.8 | Confocal microscopy and cell 
quantification
Confocal images were collected using an Andor spinning disk 
confocal microscope with NIS Elements Software (Andor 
Technology Ltd., Belfast, Northern Ireland) or an UltraView 
Nikon Ti spinning disk confocal microscope with Volocity 
software (Perkin Elmer, Waltham, USA). For quantification 
of cell density, low magnification images were taken of the 
hippocampus, entorhinal cortex and fimbria, using 20× air 
objective. Multiple z stack images (3  µm z-spacing) were 
collected using standard excitation and emission filters for 
DAPI, FITC (Alexa Fluor-488), TRITC (Alexa Fluor 568) 
and CY5 (Alexa Fluor 647) and stitched together to make a 
composite image of the entire region of interest. Each region 
of interest was defined based on Hoechst nuclear staining 
and according to the Mouse Brain Atlas (Franklin & Paxinos, 
2007) and n ≥ 3 brain sections were imaged per mouse. Cell 
quantification was performed manually using Fiji software 
(NIH, Washington DC, USA) or Adobe Photoshop. For cell 
density calculations, the total number of cells counted within 
a region of interest was divided by the total x–y area and ex-
pressed as cells per mm2 (note that z-tissue depth was always 
30 µm). All quantification from confocal images was carried 
out by an experimenter blind to age and genotype for n = 3–6 
mice per group and was additionally validated by a second 
blinded experimenter.
2.9 | Transmission electron microscopy
Mice were terminally anaesthetised using sodium pento-
barbital (i.p 100  mg/kg) and transcardially perfused with 
Karnovsky's fixative [0.8% (v/v) glutaraldehyde/2% (w/v) 
PFA/0.25 mM CaCl2/0.5 mM MgCl2 in 0.1 M sodium caco-
dylate buffer]. Brains were sliced into 2 mm thick coronal 
slices using a rodent brain matrix (Agar Scientific, Essex, 
UK) and immersion fixed at 21°C for 2  hr, before being 
stored in 0.1 M sodium cacodylate buffer overnight at 4°C. 
1mm sections of the stratum lacunosum moleculare of the 
Cornu Ammonis subfield 1 (CA1) of the hippocampus or the 
fimbria were dissected and incubated in 1% osmium tetrox-
ide/1.5% potassium ferricyanide in 0.065 M sodium caco-
dylate buffer, in the dark, for 2 hr at 4°C. Tissue was washed 
5 times in Milli-Q water, before being dehydrated in 70% 
ethanol (v/v) in Milli-Q water overnight at 21°C; 80% etha-
nol (2 × 10 min); 85% ethanol (2 × 10 min); 90% ethanol 
(2 × 10 min); 95% ethanol (2 × 10 min) and 100% ethanol 
(4 × 10 min). Tissue was embedded by serial exposure to 100% 
propylene oxide (2 × 5 min); 75% propylene oxide/25% epon 
(4 hr); 67% propylene oxide/33% epon (4 hr); 50% propylene 
oxide/50% epon (overnight); 33% propylene oxide/67% epon 
(4 hr); 25% propylene oxide/75% epon (4 hr) and 100% epon 
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(overnight). Tissue was transferred to fresh 100% epon for 4h 
before being polymerised at 60°C for 72 hr.
About 70 nm ultramicrotome (Reichert Ultracut S, Leica) 
sections were collected using a diamond knife (Diatome) 
and were floated on Milli-Q water. Floating sections were 
collected with a perfect loop (Diatome) and placed on a gold 
grid with formvar (ProSciTech) and stained with Reynolds’ 
lead citrate stain [Reynolds, 1963; lead nitrate (Sigma) and 
trisodium citrate dihydrate (Merck)] and with filtered 4% 
uranyl acetate (Serva) in 50% ethanol to enhance the con-
trast. Electron micrographs were collected using a HT7700 
(Hitachi) transmission electron microscope. Image analysis 
was carried out using Fiji software (NIH, Washington DC, 
USA). Axons were identified based on their microtubule 
organisation (reviewed by Stassart et al., 2018) and indi-
vidual myelin lamellae (wraps) by the presence of major 
dense lines (reviewed by Simons & Nave, 2016). New my-
elin was defined as myelin that contained <5 wraps as well 
as a large cytoplasmic layer (inner tongue) between the 
axon and the myelin (Kang et al., 2013; Liu et al., 2012). 
The g-ratio was measured for a minimum of 50 myelinated 
axons per region per mouse. The number of myelin wraps 
per sheath was quantified in axons that were ensheathed by 
mature compact myelin (no enlarged cytoplasmic layer) for 
a minimum of 30 axons per mouse. Quantification was per-
formed by an experimenter blind to genotype for n = 3–4 
mice per group.
2.10 | Statistical analyses
Statistical analyses were performed using GraphPad Prism 
8.0 (La Jolla CA, USA). The distribution of each data set 
was evaluated to determine whether the data were normally 
distributed using the d’Agostino and Pearson normality 
test or Shapiro–Wilk normality test as required. Data that 
were normally distributed were analysed by a parametric 
test [two-tailed unpaired t test, one-way analysis of vari-
ance (ANOVA) or two-way ANOVA for group compari-
sons with a Bonferroni post hoc test], and data that were not 
normally distributed were analysed using a non-parametric 
test [simple linear regression analysis]. A survival curve 
comparison was performed using a log-rank (Mantel-Cox) 
test. Statistical significance was established as p <  .05. p-
Values for main genotype comparisons are included in text 
where appropriate, but full statistical details are reported in 
the corresponding figure legends. Individual data points are 
presented on each graph, and further data supporting these 
findings will be made available by the corresponding author 
upon reasonable request. Behavioural data are presented as 
mean ± standard error of the mean (SEM). Western blot and 
immunohistochemical data are presented as mean ± stand-
ard deviation (SD).
3 |  RESULTS
3.1 | MAPTP301S transgenic mice do 
not develop overt locomotor or memory 
impairment by P180
Prior to examining the response of cells of the oligodendro-
cyte lineage to the earliest stages of tauopathy, we confirmed 
that human tau was expressed in brain tissue from MAPTP301S 
transgenic mice (Figure 1). Western blot analysis of the dor-
sal hippocampus indicated that human tau (Figure 1a,c) and 
phosphorylated human tau (Figure 1b,d) were expressed by 
MAPTP301S mice, but not their wild-type (WT) littermates, 
at P30, P60, P90 and P180. By comparing the relative ex-
pression of human tau (upper band, Figure 1a) and endog-
enous mouse tau (lower band, Figure 1a), we determined that 
human tau expression was twofold to fivefold more abun-
dant than mouse tau in the hippocampus of MAPTP301S mice 
(Fig.  S1a). We also found that phosphorylated human tau 
(upper band, Figure 1b) was sevenfold to 10-fold more abun-
dant than phosphorylated mouse tau (lower band, Figure 1b) 
in the hippocampus of MAPTP301S mice (Fig.  S1b). This 
transgenic overexpression of human tau was associated with 
the impaired survival of MAPTP301S transgenic mice, relative 
to their WT littermates, when they were followed until P200 
(Fig. S1c, p = .04), as well as a visible increase in reactive 
microgliosis in the hippocampus and entorhinal cortex, and 
to a lesser extent the fimbria at P180 (Fig. S2).
MAPTP301S mice typically do not develop locomo-
tor or cognitive impairments until after 10  months of age 
(Chalermpalanupap et al., 2017; Dumont et al., 2011). Before 
characterising the behaviour of oligodendrocyte lineage cells 
in the pre-symptomatic stage of disease, we first confirmed 
that the overexpression of human tau did not induce locomo-
tor or cognitive deficits before 6 months of age by subjecting 
WT and MAPTP301S mice to a battery of behavioural tasks. 
WT (Figure 1e) and MAPTP301S (Figure 1f) mice were first 
placed in an open field arena, and the distance that each mouse 
travelled (Figure  1g), and the velocity of that movement 
(Figure  1h), was mapped over a 10-min period. The over-
expression of human tau did not alter the distance travelled 
(Figure 1g, p = .06) or the velocity of movement (Figure 1h, 
p = .06) at P60, P90 or P180. WT and MAPTP301S mice also 
spent a similar proportion of time in the central area of the 
open field [P60: WT 31.9 ± 2.0%, MAPTP301S 38.2 ± 3.8%; 
P90: WT 32.2 ± 2.0%, MAPTP301S 32.3 ± 3.5%; P180: WT 
35.8 ± 1.9%, MAPTP301S 35.1 ± 3.3%, mean ± SEM; two-
way ANOVA, genotype: F (1, 94) = 0.6999, p =  .40; age: 
F (2, 94) = 0.8799, p = .41; interaction: F (2, 94) = 0.9449, 
p = .39].
Working memory was evaluated by measuring sponta-
neous alternation in the T-maze (Figure 1i). We found that 
WT and MAPTP301S mice performed similarly in this task, 
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with mice of each genotype making an equivalent number 
of errors at P60 (p = .10), P90 (p = .09) and P180 (p > .99; 
Figure 1j). Short-term recognition memory was evaluated for 
WT (Figure 1k) and MAPTP301S (Figure 1l) mice using the 
novel object recognition task. Both WT and MAPTP301S mice 
spent a larger proportion of their time exploring the novel 
object, compared with the familiar object, and we found that 
the overexpression of human tau did not affect the ability of 
mice to discriminate between the objects at P60, P90 or P180 
(Figure 1m, p = .09).
The spatial learning ability, as well as the short- and 
long-term memory performance of WT (Figure  1n) and 
MAPTP301S (Figure  1o) mice, was assessed using a Barnes 
maze spatial learning task (Fig. S3a). We found that at P60, 
P90 and P180, WT and MAPTP301S mice made fewer visits 
to incorrect holes (primary errors) on day 2 of training, com-
pared with day 1 (P60: p = .0008, P90: p = .0005 and P180: 
p = .02), suggesting that mice of both genotypes learned the 
location of the escape box (Fig. S3b-c). One day after train-
ing, during the short-term memory probe phase, P180 WT 
and MAPTP301S mice spent an equivalent amount of time in 
the target quadrant of the maze (p =  .40), and both groups 
spent more time in the target quadrant compared with all other 
quadrants (Fig.  S3d). During the long-term memory probe 
phase, two weeks after initial training, WT mice spent more 
time in the target quadrant, relative to other maze quadrants, 
while MAPTP301S mice spent an equivalent amount of time 
in all 4 quadrants (Fig. S3e). While these data may suggest 
that MAPTP301S mice are beginning to experience long-term 
memory impairment, this was not a robust phenotype, as the 
time that MAPTP301S mice spent in the target quadrant was 
equivalent to that of WT mice (Figure 1p; p = .06). Overall, 
these data indicate that human tau overexpression does not 
induce overt cognitive impairment in mice by P180.
3.2 | The number of new YFP+ cells 
produced by OPCs is elevated in P180 
MAPTP301S mice
To determine whether the overexpression of human hy-
perphosphorylated tau could influence adult oligoden-
drogenesis, prior to the onset of a behavioural change, we 
performed cre-lox lineage tracing of PDGFRα+ OPCs in 
the hippocampus, entorhinal cortex and fimbria of control 
(Pdgfrα-CreERT2::Rosa26-YFP) and MAPTP301S (Pdgfrα-
CreERT2::Rosa26-YFP::Prnp-MAPTP301S) mice. The hip-
pocampus and entorhinal cortex were selected, as they are 
among the first regions affected in human tauopathy (Du 
et al., 2001; Pennanen et al., 2004; Xu et al., 2000), and the 
fimbria is part of the major white matter tract that connects 
the hippocampi of both hemispheres and each hippocampus 
with other subcortical structures of the brain (Fimbria–fornix 
commissural pathway; Kesner & Rolls, 2015; Wyss 
et al., 1980). Tamoxifen was administered to P60 control and 
MAPTP301S mice, and brain tissue was collected at P60 + 7, 
90 or 120 days (Figure 2). Coronal cryosections containing 
the hippocampus (Figure 2a-d, Fig. S4a-h), entorhinal cor-
tex (Figure 2e-h) and fimbria (Figure 2i-l, Fig. S4i-n) were 
stained to detect of PDGFRα+ (red), yellow fluorescent pro-
tein (YFP; green), OLIG2 and Hoechst 33342 (blue). By 
quantifying the proportion of OPCs that expressed YFP, we 
determined that ~40% of OPC had undergone tamoxifen-in-
duced recombination in all brain regions examined in control 
and MAPTP301S mice (Figure 2m-o) and these YFP-labelled 
OPCs gave rise to YFP+ PDGFRα-negative cells over time 
(arrows, Figure  2a-l). Between P60  +  90 and P60  +  120, 
the proportion of YFP+ cells that were PDGFRα-negative 
significantly increased in the hippocampus (Figure  2p, 
p  =  .0005), entorhinal cortex (Figure  2q, p  <  .0001) and 
fimbria (Figure 2r, p =  .0002) of MAPTP301S mice, despite 
being largely unchanged in controls. These YFP+ PDGFRα-
negative cells were new oligodendrocytes, as they labelled 
for OLIG2. Indeed, 97.9% ± 1.4% of all YFP+ cells in the 
hippocampus of P60 + 120 control and 96.2% ± 1.3% of all 
YFP+ cells in the hippocampus of P60  +  120 MAPTP301S 
transgenic mice co-labelled with OLIG2+, confirming that 
they remain within the oligodendrocyte lineage (mean ± SD, 
unpaired t test: t = 1.17, df = 4, p = .30; n = 3 mice per geno-
type; Fig.  S4). Therefore, the density of new YFP+ oligo-
dendrocytes present in each brain region essentially doubled 
over a one-month period in MAPTP301S mice, such that by 
P60 + 120 MAPTP301S mice had significantly more new oli-
godendrocytes in the hippocampus (Figure 2s, p < .0001), en-
torhinal cortex (Figure 2t, p < .0001) and fimbria (Figure 2u, 
p < .0001), than control mice.
3.3 | Fimbria OPC proliferation is increased 
in P180 MAPTP301S mice
To determine whether human hyperphosphorylated tau 
influenced new oligodendrocyte number by modulating 
OPC proliferation, we next evaluated PDGFRα+ OPC 
density in the hippocampus (Figure 3a-c), entorhinal cor-
tex (Figure  3d) and fimbria (Figure  3e) of control and 
MAPTP301S mice at P60  +  7, P60  +  90 and P60  +  120. 
OPC density was equivalent in control and MAPTP301S 
mice (hippocampus: p  =  .17, entorhinal cortex: p  =  .28, 
fimbria: p =  .47) and did not change with age in any re-
gion (Figure 3c-e). To determine whether OPC prolifera-
tion was affected by hyperphosphorylated tau, P175 WT 
and MAPTP301S mice were given the thymidine-analogue 
EdU via their drinking water for 5 consecutive days, and 
coronal cryosections processed to detect PDGFRα (red) 
and EdU (green) (Figure  3f-k). The proportion of OPCs 
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that proliferated to incorporate EdU (EdU+ PDGFRα+/
PDGFRα+  ×  100) was equivalent in the hippocampus 
(Figure 3f, g, l; p = .81) and entorhinal cortex (Figure 3h, i, 
l; p = .97) of WT and MAPTP301S mice. By contrast, we de-
tected a small but significant increase in OPC proliferation 
in the fimbria of MAPTP301S mice, compared with WT mice 
(Figure 3j-l; p =  .0004), but this was not a large enough 
change in proliferation to overtly alter the proportion of 
OPCs that expressed the proliferative marker Ki67 at P180 
(Figure 3m-n; p = .79). Consequently, this small increase 
in fimbria OPC proliferation appears unable to explain 
the large increase in new oligodendrocyte number noted 
across the hippocampus, entorhinal cortex and fimbria of 
MAPTP301S mice at P60 + 120 (Figure 2).
3.4 | Oligodendrocyte density is normal in 
MAPTP301S mice
To determine whether the increase in new oligoden-
drocyte addition was accompanied by an overall in-
crease in oligodendrocyte number in the hippocampus 
(Figure  4a-d), entorhinal cortex (Figure  4e-h) or fim-
bria (Figure  4i-l), we performed immunohistochemis-
try on coronal brain cryosections from P120 and P180 
WT and MAPTP301S mice, to detect the oligodendrocyte 
marker aspartoacylase (ASPA). ASPA labels post-mitotic 
oligodendrocytes that also express adenomatous polypo-
sis coli clone 1 (CC1) (Howng et al., 2010; Madhavaro 
et al., 2004). We found that the density of ASPA+ oligo-
dendrocytes was unchanged between P120 and P180 in 
the hippocampus (Figure 4m; p = .30), entorhinal cortex 
(Figure  4n; p  =  .87) or fimbria (Figure  4o; p  =  .30) of 
WT or MAPTP301S mice, and that the overexpression of 
hyperphosphorylated tau did not influence total oligoden-
drocyte density in any region (hippocampus p = .52; en-
torhinal cortex p = .94; fimbria p = .45). As the number 
of newborn oligodendrocytes added to these brain regions 
in MAPTP301S mice exceeds the number added to controls 
(Figure 2), these data suggest that new oligodendrocytes 
are either (i) premyelinating oligodendrocytes that do not 
label with ASPA and contribute myelin to the brain, or 
(ii) mature oligodendrocytes that are needed to maintain 
the density of ASPA+ oligodendrocytes, rather than ex-
pand the population.
To determine whether the newborn oligodendrocytes 
added to the brains of P60 + 120 control (Pdgfrα-CreERT2:: 
Rosa26-YFP) and MAPTP301S (Pdgfrα-CreERT2::Rosa26-
YFP::Prnp-MAPTP301S) mice are immature or mature oli-
godendrocytes, coronal cryosections from ~Bregma −2.7, 
containing the hippocampus (Figure  5a-f) and entorhinal 
cortex (Figure 5g-l), were stained to detect PDGFRα+ (blue), 
YFP (green) and Breast Carcinoma Amplified Sequence 
1 (BCAS1, red), a marker of immature, premyelinating 
F I G U R E  1  MAPTP301S mice do not develop overt locomotor or memory impairment by P180 (a-b) Representative Western blots probing 
for tau protein (a; human ~55 kDa; mouse ~51 kDa) and phosphorylated Tau (pTau) protein (b; human ~55 kDa, mouse ~51 kDa) in hippocampal 
brain lysates from P30 wild-type (WT; open circles, black bars) and MAPTP301S (black squares, open bars) mice. (c) Quantification of human 
Tau protein expression relative to β-actin expression in P30, P60, P90 and P180 WT and MAPTP301S mice [two-way ANOVA, genotype: F (1, 
16) = 110, p < .0001; age: F (3, 16) = 1.034, p = .4040; interaction: F (3, 16) = 0.9767, p = .4282]. (d) Quantification of human phosphorylated 
tau expression relative to β-actin expression MAPTP301S and WT mice at P30, P60, P90 and P180 [two-way ANOVA, genotype: F (1, 16) = 148.4, 
p < .0001; age: F (3, 16) = 2.078, p = .1434; interaction: F (3, 16) = 2.004, p = .1540]. (e-f) Representative track visualisation images (EthoVision 
XT) showing movement (white lines) of P180 WT (e) and MAPTP301S (f) mice during the open field locomotor task. (g) Quantification of the 
total distance travelled by WT and MAPTP301S mice in the open field task at P60, P90 and P180 [two-way ANOVA, genotype: F (1, 94) = 3.536, 
p = .0631; age: F (2, 94) = 1.180, p = .3119; interaction: F (2, 94) = 0.767, p = .4671]. (h) Quantification of the average movement velocity of 
WT and MAPTP301S mice during the open field task at P60, P90 and P180 [two-way ANOVA, genotype: F (1, 94) = 3.466, p = .0658; age: F (2, 
94) = 1.253, p = .2904; interaction: F (2, 94) = 0.8427, p = .4338]. (i) Schematic of the T-maze apparatus. (j) Quantification of the proportion 
incorrect arm choices (errors) made by P60, P90 and P180 WT and MAPTP301S mice during the T-maze alternation task [two-way ANOVA, 
genotype: F (1, 96) = 4.317, p = .0404; age: F (2, 96) = 0.7271, p = .4859; interaction: F (2, 96) = 3.028, p = .0531]. (k-l) Representative heat 
maps (EthoVision XT) showing the relative proportion of time P180 WT (k) and MAPT (l) mice spent exploring the familiar and novel objects 
during the novel object recognition task. Warmer colours represent a greater proportion of time in that area. (m) Quantification of the proportion 
of time P60, P90, and P180 WT or MAPTP301S mice spent exploring the novel object relative to the total time spent exploring either object [two-
way ANOVA, genotype: F (1, 98) = 2.823, p = .0961; age: F (2, 98) = 2.506, p = .0868; interaction: F (2, 98) = 0.006544, p = .9935]. (n-o) 
Representative track visualisation images (EthoVision XT) showing movement (white lines) of P180 WT (n) and MAPTP301S (o) mice during the 
Barnes maze long-term memory probe trial, carried out 2 weeks after mice learned the expected location of an escape box (red arrows). Yellow 
shading indicates the quadrant of the maze defined as the target zone. (p) Quantification of the proportion of time P60, P90, and P180 WT or 
MAPTP301S mice spent within the target zone during the long-term memory probe trial [two-way ANOVA, genotype: F (1, 98) = 3.708, p = .0570; 
age: F (2, 98) = 0.5633, p = .5711; interaction: F (2, 98) = 2.623, p = .0777]. Western blot data are presented as mean ± SD, n = 3 mice per group. 
Behaviour data are presented as mean ± SEM, n = 9–24 mice per group. Asterisks denote significant differences identified by Bonferroni post hoc 
analysis, **p < .01, ***p < .001, ****p < .0001. Scale bars represent 10 cm (e-f, i, k-l) and 25 cm (n-o)
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oligodendrocytes (Fard et al., 2017). Consistent with our 
previous data, the density of new oligodendrocytes (YFP+, 
PDGFRα-negative cells) in the hippocampus (Figure  5m; 
p = .0075) and entorhinal cortex (Figure 5n; p < .0001) was 
significantly higher in P60  +  120 MAPTP301S mice com-
pared with controls; however, the density of new YFP+ oli-
godendrocytes that labelled with BCAS1, identifying them 
as premyelinating cells, was unaltered (Figure  5m-n; hip-
pocampus, p > .99; entorhinal cortex, p > .99), suggesting 
that the overexpression of hyperphosphorylated tau was not 
associated with the addition of more premyelinating cells, 
but was instead associated with an increase in the addition of 
mature oligodendrocytes.
To further confirm this, we immunolabelled coronal 
cryosections at ~Bregma −1.7, containing the hippocampus 
and fimbria, to detect PDGFRα+ (blue), YFP (green) and 
ASPA (red) (Figure 6a-h). In the hippocampus (Figure 6i) 
and fimbria (Figure 6j), we detected a small population of 
YFP+ presumptive premyelinating cells (PDGFRα-neg, 
ASPA-neg) and the density of these cells was equivalent 
between control and MAPTP301S mice. However, the density 
of YFP+ ASPA+ mature oligodendrocytes was significantly 
increased in MAPTP301S mice compared with controls, in 
both regions (Figure  6i-j; hippocampus, p  <  .0001; fim-
bria, p  =  .0023). As 284  ±  36 mature oligodendrocytes 
(mean  ±  SD) are present per mm2 of hippocampus, and 
79 ± 6 cells/mm2 are newborn (mean ± SD), this equates to 
~27% of oligodendrocytes present in the P180 MAPTP301S 
hippocampus being newborn. In the entorhinal cortex and 
fimbria, it equates to ~44% and 16%, respectively. As the 
new oligodendrocytes comprise such a large proportion of 
all oligodendrocytes in the hippocampus, entorhinal cor-
tex and fimbria of the P180 MAPTP301S mice, but do not 
increase total oligodendrocyte density beyond that seen 
in WT mice, it is likely that oligodendrocyte addition is 
accompanied by oligodendrocyte loss in the MAPTP301S 
mouse brain.
3.5 | Newly myelinated axons are more 
abundant in MAPTP301S mice
To further explore the possibility of oligodendrocyte 
turnover, we next quantified myelination in the stra-
tum lacunosum moleculare of the CA1 region of the 
hippocampus (Figure  7) and in the fimbria (Fig.  S5) of 
P180 WT and MAPTP301S mice by transmission electron 
microscopy. We found that in both regions, total axon 
density (Figure  7a-c, p  =  .76; Fig.  S5a, p  =  .79) and 
the proportion of myelinated axons (Figure 7d, p =  .99; 
Fig.  S5b, p  =  .95) were equivalent between WT and 
MAPTP301S mice. However, looking more closely at the 
myelinated axons, we found that the proportion of my-
elinated axons that were ensheathed by immature my-
elin internodes was increased in both the hippocampus 
(Figure  7d, p  =  .02) and fimbria (Fig.  S5c, p  =  .02) of 
MAPTP301S mice compared with WT mice. In cross sec-
tion, these myelin internodes were characterised by an 
enlarged cytoplasmic inner tongue process located be-
tween the axon and the initial myelin wrap (red box and 
inset Figure 7b), indicating that myelin compaction is not 
yet complete (Kang et al., 2013; Liu et al., 2012). These 
axons represent ~16% of the myelinated axon population 
in the hippocampus and ~5% of myelinated axons in the 
fimbria of MAPTP301S mice, but do not alter the g-ratio 
[axon diameter/(axon + myelin diameter)] of myelinated 
F I G U R E  2  New oligodendrocyte addition is increased in the hippocampus, entorhinal cortex and fimbria of MAPTP301S mice at P180. (a-l) 
Representative confocal images showing PDGFRα (red), YFP (green) and Hoechst (blue) in the hippocampus (a-d), entorhinal cortex (e-h) and 
fimbria (i-l) of Pdgfrα-CreERT2::Rosa26-YFP (control; a-b, e-f, i-j) and Pdgfrα-CreERT2::Rosa26-YFP::Prnp-MAPTP301S (MAPTP301S; c-d, g-h, 
k-l) mice at 90 (P60 + 90) and 120 (P60 + 120) days post tamoxifen administration (P60). (m-o) Quantification of the proportion of recombined 
OPC (YFP+ PDGFRα+/PDGFRα+) in the hippocampus [(m): two-way ANOVA, genotype: F (1, 23) = 1.272, p = .2710; age: F (2, 23) = 0.8038, 
p = .4598; interaction: F (2, 23) = 0.04821, p = .9530], the entorhinal cortex [(n): two-way ANOVA, genotype: F (1, 25) = 3.13, p = .0891; age: 
F (2, 25) = 0.982, p = .3885; interaction: F (2, 25) = 0.169, p = .8455] and the fimbria [(o): two-way ANOVA, genotype: F (1, 23) = 3.469, 
p = .0753; age: F (2, 23) = 0.3587, p = .7024; interaction: F (2, 23) = 0.02172, p = .9785] of control (open circles, black bars) and MAPTP301S 
(black squares, open bars) mice at 7, 90 and 120 days post tamoxifen administration (P60). (p-r) Quantification of the proportion of recombined 
OPCs that differentiated into new oligodendrocytes (PDGFRα-neg YFP+/YFP+) over 7, 90 and 120 days in the hippocampus [(p): two-way 
ANOVA, genotype: F (1, 23) = 18.33, p = .0003; age: F (2, 23) = 20.33, p < .0001; interaction: F (2, 23) = 11.70, p = .0003], the entorhinal 
cortex [(q): two-way ANOVA, genotype: F (1, 25) = 9.489, p = .0050; age: F (2, 25) = 34.13, p < .0001; interaction: F (2, 25) = 15.42, p < .0001] 
and the fimbria [(r): two-way ANOVA, genotype: F (1, 23) = 10.18, p = .0041; age: F (2, 23) = 58.20, p < .0001; interaction: F (2, 23) = 10.49, 
p = .0006] of control and MAPTP301S mice. (s-u) Quantification of the density of new oligodendrocytes (PDGFRα-neg YFP+/mm2) added to the 
hippocampus [(s): two-way ANOVA, genotype: F (1, 23) = 23.09, p < .0001; age: F (2, 23) = 20.88, p < .0001; interaction: F (2, 23) = 15.26, 
p < .0001], the entorhinal cortex [(t): two-way ANOVA, genotype: F (1, 25) = 14.94, p = .0007; age: F (2, 25) = 18.28, p < .0001; interaction: 
F (2, 25) = 14.37, p < .0001] and the fimbria [(u): two-way ANOVA, genotype: F (1, 23) = 26.15, p < .0001; age: F (2, 23) = 35.02, p < .0001; 
interaction: F (2, 23) = 21.65, p < .0001]. Data are presented as mean ± SD, n = 3–13 mice per group. Asterisks indicate significant differences 
identified by Bonferroni post hoc analysis, ****p < .0001. Scale bars represent 30 µm. Arrows indicate YFP+ PDGFRα+ recombined OPCs. Arrow 
heads indicate YFP+ PDGFRα-neg newly added oligodendrocytes
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axons in either region (hippocampus: Figure 7e-I; fimbria: 
Fig.  S5d), or the average g-ratio per mouse (Figure  7j, 
p = .55; Fig. S5e, p = .25). The average number of my-
elin wraps per mature myelin sheath (Figure 7k, p = .73) 
was also equivalent between WT and MAPTP301S mice. 
As more axons were newly ensheathed in the hippocam-
pus and fimbria of P180 MAPTP301S mice than WT mice, 
yet the overall level of myelination is the same, new oli-
godendrocytes must engage in myelin replacement in the 
early stages of taupathology in this preclinical model.
4 |  DISCUSSION
Myelin and axon losses are associated with cognitive decline 
and are exacerbated in people diagnosed with tauopathy. 
However, the behaviour of OPCs early in the disease process 
and the potential for myelin repair remain unclear. Herein, 
by tracing the fate of OPCs in MAPTP301S transgenic mice, 
we show that the number of adult-born oligodendrocytes in-
creases in the hippocampus, entorhinal cortex and fimbria 
between 5 and 6 months of age, prior to the onset of overt 
cognitive symptoms. This increase in new oligodendrocyte 
addition cannot be explained by an equivalent increase in 
OPC proliferation and was not associated with a change in 
total oligodendrocyte density, or the number of axons that 
were myelinated within the hippocampus or fimbria; how-
ever, a larger proportion of the axons were ensheathed by im-
mature myelin internodes, which may be indicative of myelin 
repair.
4.1 | MAPTP301S transgenic mice do not 
develop overt motor or cognitive deficits by 
6 months of age
MAPTP301S transgenic mice overexpress the T34 isoform of 
human MAPT (1N4R) with the P301S mutation under the 
regulation of the mouse prion promotor, resulting in human 
tau protein being expressed in the brain at levels that are 5 
times higher than the endogenous mouse protein (Yoshiyama 
et al., 2007). To determine whether the relative expression of 
human tau protein changed with age in the hippocampus, we 
performed western blot analysis of hippocampal lysates from 
P30, P60, P90 and P180 mice. We found that human tau and 
hyperphosphorylated human tau were not detected in WT 
mice, but were abundantly expressed in MAPTP301S mice, 
and that their relative expression levels remained stable over 
time (Figure 1). When MAPTP301S mice are maintained on a 
B6C3H genetic background, they exhibit prominent micro-
glial activation from 3 months of age, prior to the formation of 
neurofibrillary tangles at 6 months of age (Yoshiyama et al., 
2007). However, when we maintain the MAPTP301S mice on 
a C57BL/6 background, we detect microglial activation at 
6 months of age (Fig. S2), and they develop neurofibrillary 
tangles at 10 months of age (Dumont et al., 2011), suggesting 
that the genetic background of these mice can significantly 
impact the time course of their pathology. The more severe 
phenotype of MAPTP301S mice on a B6C3H background is 
further supported by poorer survival outcomes with ~25% 
dying by 6 months of age (Yoshiyama et al., 2007) compared 
with only ~15% of mice dying within the first 6 months when 
they are crossed onto a C57BL/6 background (Merchán-
Rubira et al., 2019; our Fig. S1).
Tauopathies are associated with progressive motor degen-
eration and cognitive impairment (Lewis et al., 2000; Ramsden 
et al., 2005; Santacruz et al., 2005; Yoshiyama et al., 2007; 
Takeuchi et al., 2011; reviewed by Ferrer, 2018). To determine 
whether MAPTP301S mice had impaired locomotor or cognitive 
performance, they were subjected to a battery of behavioural 
tests at 2, 3 and 6 months of age. We found that MAPTP301S 
mice displayed normal locomotion in an open field task, at 
least until 6 months of age (Figure 1), suggesting there was 
no overt impairment in motor function. MAPTP301S overex-
pression also had no effect on working memory performance 
in the T-maze, short-term recognition memory in the novel 
F I G U R E  3  OPC proliferation is increased in the fimbria of MAPTP301S mice at P180. (a-b) Representative confocal image stacks showing 
Pdgfrα labelling in the hippocampus of Pdgfrα-CreERT2::Rosa26-YFP (control; a) and Pdgfrα-CreERT2::Rosa26-YFP::Prnp-MAPTP301S 
(MAPTP301S; b) mice at 120 days post tamoxifen administration (P60). (c-e) Quantification of OPC density (Pdgfrα+/mm2) in the hippocampus 
[(c): two-way ANOVA, genotype: F (1, 23) = 1.938, p = .1772; age: F (2, 23) = 0.3121, p = .7349; interaction: F (2, 23) = 2.015, p = .1562], 
the entorhinal cortex [(d): two-way ANOVA, genotype: F (1, 25) = 1.188, p = .2861; age: F (2, 25) = 1.162, p = .3292; interaction: F (2, 25) = 
3.189, p = .0584] and the fimbria [(e): two-way ANOVA, genotype: F (1, 23) = 0.5396, p = .4700; age: F (2, 23) = 12.37, p = .0002; interaction: 
F (2, 23) = 0.2118, p = .8107] of control (open circles, black bars) and MAPTP301S (black squares, open bars) mice. (f-k) Representative confocal 
image stacks showing PDGFRα (red), EdU (green) and Hoescht 33342 (blue) labelling in the hippocampus (f-g), entorhinal cortex (h-i) and fimbria 
(j-k) of P180 wild-type (WT; open circles, black bars) and MAPTP301S (black squares, open bars) mice following 5 days of EdU administration. 
(l) Quantification of the proportion of EdU+ OPCs (EdU+ PDGFRα+/PDGFRα+) in the hippocampus, entorhinal cortex and fimbria of WT and 
MAPTP301S mice [(l): two-way ANOVA, genotype: F (1, 20) = 11.98, p = .0025; brain region: F (2, 20) = 121.7, p < .0001; interaction: F (2, 20) = 
5.997, p = .0091]. (m-n) Representative confocal images showing cells expressing PDGFRα (red) and Ki67 (green) in the fimbria of P180 WT (m) 
and MAPTP301S (n) mice. (o) Quantification of the proportion of Ki67+ OPC (Ki67+ PDGFRα+/PDGFRα+) at P180 within the fimbria (two-tailed, 
unpaired t test, p = .798). Data are presented as mean ± SD for n = 3–6 mice per group. Arrows indicate PDGFRα+ OPCs. Arrow heads indicate 
recently divided OPCs (EdU+ PDGFRα+). Scale bars represent 80 µm (a-b); 40 µm (f-k); 20 µm (m-n)
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object recognition task, or spatial learning and memory in the 
Barnes maze at any age examined (Figure 1), suggesting that 
these mice do not exhibit a decline in cognitive performance 
until after 6  months of age. Overexpression of the P301L 
mutation of human MAPT, under the mouse prion promotor, 
results in a rapid decline in motor function from as early as 
4.5 months of age in homozygous and 6.5 months in hetero-
zygous mice (Lewis et al., 2000). However, consistent with 
our data, motor decline is not observed in mice overexpress-
ing the P301S mutation under the same promotor (Dumont 
et al., 2011; Takeuchi et al., 2011; Chalermpalanupap et al., 
2017; our Figure 1). Instead, transient increases in locomotor 
behaviour in an open field arena have been reported that are 
either only seen between 30 and 90 min of a 2-hr observation 
time (Takeuchi et al., 2011), or present at 7  months of age 
but not at 10 months (Dumont et al., 2011). For MAPTP301S 
mice raised on the B6CH3 background, deficits in spatial 
memory and contextual fear conditioning have been reported 
at 6 (Takeuchi et al., 2011) and 7.5 (Lasagna-Reeves et al., 
2016) months of age. However, consistent with our data, 
other studies examining MAPTP301S mice on a C57BL/6 back-
ground show that the onset of memory impairment is delayed 
until after 10 months of age (Chalermpalanupap et al., 2017; 
Dumont et al., 2011), such that their performance in a Barnes 
maze is equivalent to WT mice at 6 months of age (Takeuchi 
et al., 2011). Our data provide further support that MAPTP301S 
mice maintained on a C57BL/6 background do not exhibit 
overt motor impairment or cognitive decline by 6 months of 
age. Therefore, cellular changes identified ≤6 months of age 
can be considered pre-symptomatic in these mice.
4.2 | The number of new oligodendrocytes 
added to the brain of MAPTP301S mice 
increases between 5 and 6 months of age
OPCs continue to generate new oligodendrocytes at dif-
ferent rates in the adult mouse brain grey and white matter 
(Dimou, Simon, Kirchhoff, Takebayashi, & Gotz, 2008; 
Fukushima et al., 2015; Hill, Patel, Medved, Reiss, & 
Nishiyama, 2013; Rivers et al., 2008; Young et al., 2013). 
While the rate of OPC proliferation and oligodendrocyte 
addition slows with ageing in the mouse CNS (reviewed 
by Wang & Young, 2014), experimental interventions 
that produce demyelination have been shown to stimulate 
OPC proliferation and result in the rapid replacement of 
oligodendrocytes and remyelination (Assinck et al., 2017; 
Baxi et al., 2017; Tripathi et al., 2010; Zawadzka et al., 
2010). To determine whether overexpression of the human 
MAPTP301S variant in mice was associated with a change 
in OPC behaviour and new oligodendrocyte addition, we 
fluorescently labelled OPCs and followed their fate over-
time (Figure  2; Fig.  S4). Essentially, all of the cells that 
became YFP-labelled were of the oligodendrocyte lineage 
(Fig. S4) confirming that newly differentiated OPCs (YFP+ 
PDGFRα-negative) were newborn oligodendrocytes. We 
found that a small number of newborn YFP-labelled oligo-
dendrocytes accumulated in the hippocampus, entorhinal 
cortex and fimbria of control and MAPTP301S transgenic 
mice between P60 and P150, and that the rate of oligoden-
drocyte addition during this time period was not affected by 
MAPTP301S expression. However, between P150 and P180, 
when oligodendrocyte addition was negligible in control 
mice, the number of YFP-labelled oligodendrocytes in-
creased significantly in the MAPTP301S transgenic mice, in 
each of the brain regions examined. Previous studies have 
not examined oligodendrogenesis in MAPTP301S transgenic 
mice; however, there is some evidence that oligodendro-
genesis is increased in P60 adult Thy1.2-MAPTP301S trans-
genic mice following toxin-induced focal demyelination 
of the ventral funiculus in the spinal cord (Ossola et al., 
2016). Fourteen days after demyelination, the density of 
APC+ OLIG2+ oligodendrocytes was increased in the le-
sion site of Thy1.2-MAPTP301S transgenic mice compared 
with WT lesioned mice (Ossola et al., 2016), confirming 
the capacity for OPCs to efficiently remyelinate the injured 
CNS in the early stages of tau pathology.
A large increase in oligodendrocyte generation is often 
accompanied by an increase in OPC proliferation, as OPC 
differentiation stimulates the proliferation of adjacent OPCs 
to sustain the OPC population (Hughes, Kang, Fukaya, & 
Bergles, 2013). To determine whether expression of the 
human MAPTP301S variant, and the associated increase in 
new oligodendrocyte number, was associated with elevated 
OPC proliferation, dividing OPCs were EdU-labelled in the 
brain of 6-month-old control and MAPTP301S transgenic mice 
(Figure 3). While OPC proliferation was elevated in the fim-
bria of MAPTP301S transgenic mice, when compared with the 
F I G U R E  4  Oligodendrocyte population is not altered in MAPTP301S mice at P120 and P180. (a-l) Representative confocal images of ASPA 
(red) and Hoechst 33342 (blue) in the hippocampus (a-d), entorhinal cortex (EC; e-h) and fimbria (i-l) of wild-type (WT) and MAPTP301S mice at 
P120 and P180. (m-o) Quantification of total oligodendrocyte density (ASPA+/mm2) in the hippocampus [(m): two-way ANOVA, genotype: F 
(1, 17) = 0.417, p = .526; age: F (1, 17) = 0.849, p = .369; interaction: (1, 17) = 1.100, p = .308], the entorhinal cortex [(n): two-way ANOVA, 
genotype: F (1, 18) = 0.004, p = .948; age: F (1, 18) = 0.0254, p = .875; interaction: F (1, 18) = 0.397, p = .536] and the fimbria [(o): two-way 
ANOVA, genotype: F (1, 14) = 0.594, p = .453; age: F (1, 14) = 1.145, p = .302; interaction: F (1, 14) = 0.080, p = .781] of WT (open circles, 
black bars) and MAPTP301S (black squares, open bars) mice at P120 and P180. Data are presented as mean ± SD, n = 3–5 mice per group. Scale 
bars represent 40 µm
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wild-type littermates, it was not elevated in the hippocam-
pus or entorhinal cortex. These data could be explained by 
an increase in oligodendrogenesis occurring close to P150, 
such that OPC proliferation has returned to normal by P180. 
Alternatively, we have previously shown that new oligoden-
drocyte number can be increased in response to transcranial 
magnetic stimulation, by enhancing the survival of the new-
born cells (Cullen et al., 2019). Increased adenosine triphos-
phate production, through the availability of creatine, can 
also enhance oligodendrocyte survival during inflammation 
or after demyelination (Chamberlain, Chapey, Nanescu, & 
Huang, 2017). Therefore, it is possible that oligodendrocyte 
loss or other stimuli could enhance newborn oligodendrocyte 
survival in the MAPTP301S transgenic mice. Indeed, a com-
bination of increased cell generation and improved survival 
would likely be needed to account for the substantial increase 
in new oligodendrocyte number observed over a one-month 
period in the MAPTP301S transgenic mice.
4.3 | Is oligodendrocyte turnover increased 
in MAPTP301S transgenic mice?
To determine whether the large number of new oligoden-
drocytes added to the hippocampus, entorhinal cortex and 
fimbria of MAPTP301S mice increased the total number of 
oligodendrocytes, or acted to replace oligodendrocytes lost 
to pathology, we quantified ASPA+ oligodendrocyte density 
(Figure  4) as well as the proportion of newborn oligoden-
drocytes that were immature (BCAS1+/ASPA-negative) or 
mature (ASPA+/ BCAS1-negative) oligodendrocytes in 
each region (Figure 5 and Figure 6). Overall, oligodendro-
cyte density was significantly higher in the fimbria than in 
the hippocampus or entorhinal cortex, but for each region, 
it was equivalent between WT and MAPTP301S transgenic 
mice (Figure 4). In the MAPTP301S transgenic mice, however, 
a larger proportion of these cells were added and matured 
between 5 and 6 months of age (Figures 5 and 6), suggesting 
that oligodendrocyte replacement had occurred. To confirm 
that this phenotype was not associated with neuron loss, we 
quantified axon density and the proportion of axons that are 
myelinated (Figure 7) in the CA1 subfield of the hippocampus 
and in the fimbria and found that was also normal in 6-month-
old MAPTP301S transgenic mice. Overall, the proportion of 
axons that were myelinated, and their myelin thickness was 
also equivalent to that of WT mice. However, MAPTP301S had 
approximately twice as many axons ensheathed by immature 
or new myelin internodes (Figure 7 and Fig. S5).
Immature myelin is characterised by the presence of a 
thick cytoplasmic tongue process, forming the inner layer 
between the axon and the first compact myelin wrap (Kang 
et al., 2013; Liu et al., 2012), and suggests that the new oli-
godendrocytes participate in de novo myelination or myelin 
repair within these regions. At P180, the newborn oligoden-
drocytes comprise a significant proportion of all oligoden-
drocytes detected in the grey matter regions of MAPTP301S 
transgenic mice, making it unlikely that they would not alter 
the total oligodendrocyte addition or the proportion of axons 
that are myelinated, unless the increase in new oligodendro-
cyte number and new myelin sheath addition was accompa-
nied by oligodendrocyte death. Therefore, we suggest that 
oligodendrocyte addition between P150 and P180 is driven by 
the need for oligodendrocyte replacement in the MAPTP301S 
transgenic mice and propose that these oligodendrocytes act 
to maintain myelin at this early stage of tauopathy.
It is well established that tauopathy can directly or indi-
rectly result in oligodendrocyte death. For example, overex-
pression of the MAPTP301L variant, under the mouse α-tubulin 
promotor, causes the formation of  coiled filamentous tau+ 
inclusions in spinal cord oligodendrocytes, subsequently 
leading to oligodendrocyte degeneration and the loss of their 
associated myelin (Higuchi et al., 2002). Additionally, spi-
nal cord oligodendrocytes undergo apopotosis in the Prnp-
MAPTP301L mouse model of tauopathy (Zehr et al., 2004). 
As oligodendrocytes express tau (Cullen et al., 2019; Young 
et al., 2013), it is possible that oligodendrocytes undergo 
apopotosis due to a direct effect of hyperphosphorylated 
tau; however, in the Prnp-MAPTP301L and MAPTP301S mouse 
F I G U R E  5  P60 + 120 MAPTP301S and control mice have a similar number of newborn BCAS1+ premyelinating oligodendrocytes in 
the hippocampus and entorhinal cortex. (a-f) Representative confocal images showing BCAS1 (red), PDGFRα (blue) and YFP (green) in the 
hippocampus of P60 + 120 Pdgfrα-CreERT2::Rosa26-YFP (control; a-c) and Pdgfrα-CreERT2::Rosa26-YFP::Prnp-MAPTP301S (MAPTP301S; d-f) 
mice at ~Bregma −2.7. (g-l) Representative confocal images showing BCAS1 (red), PDGFRα (blue) and YFP (green) in the entorhinal cortex (EC) 
of P60 + 120 Pdgfrα-CreERT2::Rosa26-YFP (control; g-i) and Pdgfrα-CreERT2::Rosa26-YFP::Prnp-MAPTP301S (MAPTP301S; j-l) mice at ~Bregma 
−2.7. (m) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the hippocampus of P60 + 120 control and MAPTP301S 
mice, including those that are YFP+ PDGFRα-negative BCAS1+ premyelinating oligodendrocytes versus YFP+ PDGFRα-negative BCAS1-
negative mature oligodendrocytes. [two-way ANOVA, genotype: F (1, 21) = 15.73, p = .0007; cell type: F (2, 21) = 18.59, p < .0001; interaction: 
F (2, 21) = 4.428., p = .024]. (n) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the entorhinal cortex of P60 + 120 
control and MAPTP301S mice, including those that are YFP+ PDGFRα-negative BCAS1+ premyelinating oligodendrocytes versus YFP+ PDGFRα-
negative BCAS1-negative mature oligodendrocytes. [two-way ANOVA, genotype: F (1, 21) = 46.37, p < .0001; cell type: F (2, 21) = 38.57, 
p < .0001; interaction: F (2, 21) = 8.00, p = .002]. Asterisks indicate significant differences identified by Bonferroni post hoc analysis, **p < .01, 
***p < .001, ****p < .0001. Scale bars represent 35 µm
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models of tauopathy, oligodendrocyte death is more likely 
a secondary consequence of tauopathy, as the expression of 
hyperphosphorylated tau is directed by the prion protein pro-
motor in both instances. The mRNA encoding for the prion 
protein is expressed by nearly all cells within the mouse brain 
(Hrvatin et al., 2018; Zhang et al., 2014); however, when the 
mouse prion promotor is used to drive transcription of a re-
porter protein (e.g., LacZ), expression is primarily detected 
in neuronal populations, including hippocampal pyramidal 
and granule neurons that project through the fimbria (Bailly 
et al., 2004), and is detected in very few cells within white 
matter regions (Tremblay et al., 2007) where oligodendro-
cytes are concentrated.
Other models of neurodegenerative disease have also 
demonstrated increased oligodendrocyte turnover prior to 
the onset of disease symptoms (Behrendt et al., 2013; Desai 
et al., 2009, 2010; Dong et al., 2018; Kang et al., 2013). For 
example, oligodendrocyte loss and myelin abnormalities are 
observed by 6 months of age, prior to the onset of amyloid pa-
thology, in mouse models of familial Alzheimer's disease that 
F I G U R E  6  MAPTP301S mice add more ASPA+ mature oligodendrocytes to the hippocampus and fimbria than control mice between 5 
and 6 months of age. (a-h) Confocal images showing ASPA (red), PDGFRα (blue) and YFP (green) in the hippocampus of P60 + 120 Pdgfrα-
CreERT2:: Rosa26-YFP (control; a-d) and Pdgfrα-CreERT2:: Rosa26-YFP:: Prnp-MAPTP301S (MAPTP301S; e-h) mice at ~Bregma −1.7. (m) 
Quantification of the density of all YFP+ cells that are PDGFRα-negative in the hippocampus of P60 + 120 control and MAPTP301S mice, including 
those that are YFP+ PDGFRα-negative ASPA-negative premyelinating oligodendrocytes versus YFP+ PDGFRα-negative ASPA+ mature 
oligodendrocytes. [two-way ANOVA, genotype: F (1, 12) = 120.5, p < .0001; cell type: F (2, 12) = 79.72, p < .0001; interaction: F (2, 12) = 
25.19, p < .0001]. (n) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the fimbria of P60 + 120 control and MAPTP301S 
mice, including those that are YFP+ PDGFRα-negative ASPA-negative premyelinating oligodendrocytes versus YFP+ PDGFRα-negative ASPA+ 
mature oligodendrocytes. [two-way ANOVA, genotype: F (1, 12) = 40.81, p < .0001; age: F (2, 12) = 15.27, p = .0005; interaction: F (2, 12) = 
5.46, p = .02]. Asterisks indicate significant differences identified by Bonferroni post hoc analysis, **p < .01, ***p < .001, ****p < .0001. Scale 
bars represent 35µm
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overexpress human mutations in the amyloid precursor and 
presenilin 1 proteins, either alone (APP/PS1 mice; Behrendt 
et al., 2013; Dong et al., 2018) or in combination with the 
MAPTP301L mutation (3xTg mice; Desai et al., 2010; Desai 
et al., 2009). This was often accompanied by an increase in 
OPC number and oligodendrocyte generation at the same age, 
suggesting recruitment of these cells to repair myelin dam-
age early in disease (Behrendt et al., 2013; Desai et al., 2010; 
Dong et al., 2018). Similarly, in a SOD1 mouse model of amy-
otrophic lateral sclerosis, oligodendrocyte loss occurs prior to 
F I G U R E  7  The proportion of newly myelinated axons is increased in MAPTP301S mice at P180. (a-b) Representative electron micrographs 
from the CA1 region of the hippocampus of WT (a) and MAPTP301S (b) mice at P180. Red box and inset (b) show a newly myelinated axon 
(c) Quantification of axon density (axons/µm2) in WT (open circles) and MAPTP301S (black squares) mice (two-tailed t test, t = 0.3133, df = 6, 
p = .7647). (d) Quantification of the proportion of myelinated axons in the CA1 of WT and MAPTP301S mice at P180 (two-tailed t test, t = 0.003, 
df = 6 p = .9970). (e) Quantification of the proportion of myelinated axons ensheathed by immature (new) myelin (two-tailed t test, t = 3.027, 
df = 6, p = .0232). (f) Graphical representation of the g-ratio distribution based on axon diameter (Simple linear regression analysis, slope F (1, 
1,062) = 1.344, p = .2466, Y intercept F (1, 1,063) = 0.1533, p = .6955 n = 55–190 myelinated axons per mouse). (g) Quantification of average 
g-ratio per animal in WT and MAPTP301S mice at P180 (two-tailed t test, t = 0.6236, df = 6, p = .5558). (h-i) Representative high magnification 
electron micrographs through a single myelinated axon within the CA1 region of the number of myelin wraps in WT (h) and MAPT mice (i) at 
P180. (j) Quantification of average myelin wraps per animal in WT and MAPTP301S mice at P180 (two-tailed t test, t = 0.3533, df = 6, p = .7359). 
Scale bars represent: 1 µm (a-b), 300 nm and 100 nm (h, i). Results are presented as mean ± SD, n = 4 mice per genotype
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the onset of disease symptoms and coincides with increased 
oligodendrogenesis, and acts to maintain a consistent popula-
tion of oligodendrocytes within the spinal cord through to the 
end stage of disease (Kang et al., 2013). Consistent with our 
data, increased oligodendrocyte turnover was accompanied by 
an increase in the proportion of axons that were ensheathed by 
immature myelin, suggesting that these axons had been remy-
elinated (Kang et al., 2013). Collectively, these data indicate 
that oligodendrocyte turnover is a common early feature of 
neurodegenerative diseases associated with abnormal protein 
aggregation, suggesting that oligodendrocytes are highly sus-
ceptible to disease-related stresses prior to the onset of disease 
symptoms. We propose that therapeutic approaches being de-
veloped to promote oligodendrocyte survival or enhancement 
of myelin repair for diseases such as multiple sclerosis may 
also be beneficial in the early stages of other neurodegenera-
tive diseases such as tauopathies.
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